Table 2.
Timing of immunotherapy and epilepsy markers.
| Case 1 | Case 2 | Case 3 | |
|---|---|---|---|
| Time (days) Between IVIg and … | |||
| 1st Seizure | 7 | 4 | 11 |
| Refractory SE | 34 | 14 | 1st: 93 2nd: 4 |
| Ketamine Infusion | 43 | 18 | 1st: 125 2nd: 36 |
| Discontinuation of SE | 44 | 19 | 1st: 127 2nd: 38 |
| Time (days) Between IV methylprednisolone and … | |||
| 1st Seizure | 7 | 4 | 11 |
| Refractory SE | 34 | 14 | 93 |
| Ketamine Infusion | 43 | 18 | 125 |
| Discontinuation of SE | 44 | 19 | 127 |
| Time (days) Between 1st Infusion of Rituximab and | |||
| 1st Seizure | n/a | n/a | n/a |
| Refractory SE | 21 | 10 | n/a |
| Ketamine Infusion | 30 | 14 | n/a |
| Discontinuation of SE | 31 | 15 | n/a |
| Time (days) between CD19/20% at 0 and Ketamine use … | 19 | 7 | 120 |